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This article highlights trends in heart transplantation
from 1998 to 2007, using data from the Organ Procure-
ment and Transplantation Network (OPTN) and the Sci-
entific Registry of Transplant Recipients (SRTR). The
number of candidates actively awaiting heart trans-
plantation has declined steadily, from 2525 in 1998 to
1408 in 2007, a 44% decrease. Despite this decline, a
larger proportion of patients are listed as either Status
1A or 1B, likely secondary to increased use of mechan-
ical circulatory support. During this time, the overall
death rate among patients awaiting heart transplanta-
tion fell from 220 to 142 patients per 1000 patient-years
at risk; this likely reflects better medical and surgical
options for those with end-stage heart failure. This
trend was noted across all racial groups, both sexes,
all disease etiologies (retransplantation excepted) and
all status groups. Recipient numbers were relatively
stable over the past decade. In 2007, 2207 transplants
were performed, although the proportion of patients
transplanted as Status 1A shifted from 34% to 50%.
A trend toward transplanting more patients above 65
years of age was seen. Adjusted patient (and graft)
survival at 3 months, 1, 5 and 10 years after transplan-
tation has gradually, but significantly, improved during
the same period; current patient survival estimates are
93%, 88%, 74% and 55%, respectively.
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Introduction
This article reviews recent trends in heart transplantation
in the United States. The data reported here are drawn
from the 2008 OPTN/SRTR Annual Report and cover all as-
pects of heart transplantation over the last 10 years (1). The
most recent change in the heart allocation system—the in-
creased geographic sharing of hearts introduced on July
12, 2006—is having noticeable effects on transplantation
trends. The broader sharing of hearts to patients with more
urgent status designations increases access to organs for
sicker candidates at greater distances in exchange for de-
creasing access to organs for more stable local patients.
The data available for evaluating the beneficial effects of
this allocation change remain limited, particularly in regard
to posttransplant outcomes, but interesting results are be-
coming apparent, including improved waiting list survival.
Improvement of the heart allocation policy is an ongoing
process, particularly as new data elements are identified
that may enhance the ability of the system to make the
best use of this scarce resource.
Heart Waiting List and Recipient
Characteristics
Candidate characteristics
The characteristics of heart transplant candidates are de-
rived from patients actively awaiting heart transplantation
at the end of each calendar year from 1998 to 2007. Over-
all, the number of active candidates declined 44% over
the decade, from 2525 patients in 1998 to 1408 in 2007
[Table 11.1a].
When examined by age, there was a modest but consis-
tent increase on the active list in the proportion of pedi-
atric patients, that is, those younger than 18 years (from
4% to 8% of the total number of candidates), as well
as those over 65 years (from 7% to 12%) [Table 11.1a].
The demographics of the waiting list have changed slightly
over the last 10 years. There has been a decrease in the
proportion of white candidates (from 80% to 74%) and
an increase in the proportion of both African American
candidates (from 14% to 17%) and Hispanic/Latino can-
didates (from 5% to 7%). Candidate sex has also shifted
from 20% to 25% female. Country of residence has re-
mained stable, with 99.6% of patients residing within the
United States. There persists a small, gradual, but sus-
tained increase in candidates who themselves are recip-
ients of other solid organ transplants (from 3% to 6%)
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Source: 2008 OPTN/SRTR Annual Report, Table 11.1a.
Figure 1: Status of heart trans-
plant waiting list candidates,
2001–2007.
most in the form of candidates waiting for heart retrans-
plant (from 3% to 5%). The proportion of candidates with
coronary artery disease has decreased from 47% to 42%;
the proportion with congenital heart disease has increased
from 4% to 8%. The proportion of other diagnosis groups
has remained similar across the decade (currently, primary
cardiomyopathy in 41% and valvular disease in 2%)
[Table 11.1a].
The criteria by which adult patients are assigned a wait-
ing list status (1A, 1B and 2) have not changed substan-
tially since 1999 (the policy change in that year replacing
Status 1 with 1A and 1B). Currently, Status 1A patients
meet one or more of the following criteria: (1) mechan-
ical circulatory support (defined as either a right and/or
left ventricular assist device [RVAD and/or LVAD], with
30 days of Status 1A time allocated at the discretion of
the transplant center), intra-aortic balloon pump, total ar-
tificial heart or extracorporeal life support/membrane oxy-
genation (ECLS/ECMO); (2) mechanical circulatory support
with objective evidence of device-related complication; (3)
mechanical ventilation; (4) high dose or multiple inotropes















Source: 2008 OPTN/SRTR Annual Report, Table 11.2b.
Figure 2: Condition of Status 1A
patients on heart waiting list as of
January 1, 2007 at 30, 60 and 90
days snapshots.
sures or (5) other exceptional cases. Status 1B patients
have either: (a) a ventricular assist device (VAD) beyond
the 30 days of discretionary time and without evidence of
device-related complication or (b) continuous infusion of
inotropes without hemodynamic monitoring. Status 2 pa-
tients are all others not meeting criteria for Status 1A or
1B. Status 7 patients are inactive. There has been a slow
but persistent increase in the proportion of Status 1A and
1B patients and a gradual decline in Status 2 patients over
the last several years (Figure 1). This may be due to in-
creased utilization of VADs as a bridge to transplant. Also,
many centers choose not to pursue active listing for pa-
tients who are unlikely to receive an organ offer unless
their clinical status deteriorates to the point of qualifying
for Status 1A or 1B; this is the case for heavier patients of
blood types O or A. In addition, there is some degree of
doubt that all patients who are classified as ‘stable’ Status
2 receive mortality benefit from transplantation, particu-
larly in the era of improved medical and anti-arrhythmia
therapy. In concert with this, there has been a steady in-
crease in the proportion of patients transplanted within the
first 30 days of listing [Table 11.1a]. In 2006 and 2007, of
those patients newly listed as Status 1A, 22.6% of patients

















Source: 2008 OPTN/SRTR Annual Report, Table 11.2b.
Figure 3: Condition of Status 1B
patients on heart waiting list as of
January 1, 2007 at 30, 60 and 90
days snapshots.
were transplanted after 7 days and 47.2% by 30 days (1.9%
died by 7 days and 6.8% died by 30 days) [Table 11.2a].
Of those patients on the waiting list on January 1, 2007
(regardless of waiting time accrued), the following obser-
vations can be made: (1) Among Status 1A patients, 13%
were ‘downgraded’ to Status 1B and waiting list mortality
was stable over the subsequent 90-day period. (2) Among
1B patients, 10% were ‘upgraded’ to 1A over the first 60
days and 38% were transplanted by 90 days; there was a
gradual increase in mortality over the period from 1.1% to
4.2%. (3) Only 10% of Status 2 patients were transplanted,
with a waiting list mortality of 1.8% within the subsequent
90 days (Figures 2–4) [Table 11.2b]. There is also a sus-
tained proportion (approximately 30–37%) of patients who
wait more than 1 year. Interestingly, the number of inactive
patients has remained surprisingly high—1251 patients at
year-end in 2007 (47% of the entire list vs. 38% of the
entire list in 1998 at year-end) [Table 11.1b].
Deaths on the waiting list
The overall death rate of patients awaiting heart transplan-
tation has decreased over the past 10 years, from 220
per 1000 patient-years at risk in 1998 to 142 per 1000
patient-years at risk in 2007 (Figure 5) [Table 11.3]. This
trend was true across all adult age groups. Because of
the relatively few numbers of pediatric patients, it is dif-
ficult to assign any level of certainty to trends associ-
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Source: 2008 OPTN/SRTR Annual Report, Table 11.2b.
Figure 4: Condition of Status 2 pa-
tients on heart waiting list as of
January 1, 2007 at 30, 60 and 90
days snapshots.
over the decade also were seen across major categories
of race/ethnicity, sex, blood type (with too few in blood
type AB for meaningful analysis) and diagnosis, with the
exception of retransplant candidates [Table 11.3]. When ex-
amined by urgency status, the decline in waiting list mor-
tality was evident across Status 1A, 1B and 2, although
it was most pronounced for patients listed as Status 1A
(Figure 6). This potentially reflects the impact of increased
used of LVADs, and, perhaps for 2007 data, the regional
sharing policy for Status 1A and 1B recipients that be-
gan in July 2006 (see later the Heart Allocation Policy
Changes section). It should be noted that, although the
decreased overall death rate is encouraging, the degree of
illness for those listed as well as background medical and
device therapy have also likely changed. Because of this,
caution should be used when comparing these data from
era to era.
Recipient characteristics
The overall number of heart transplants performed in the
United States has varied by 14% over the past decade,
from a high of 2348 in 1998 to a low of 2015 in 2004.
After reaching that 10-year low in 2004, the number of
heart transplants increased slightly in each of the past
3 years to a total of 2207 in 2007 (Figure 7) [Table 11.4].
There was also a 16% decrease in the rate of heart trans-
plants per million U.S. residents over the last 10 years,
although this trend appears to have leveled off over the
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Figure 5: Annual death rate of pa-
tients awaiting heart transplanta-
tion per 1000 patient-years at risk
1998–2007.
last few years (Figure 7) [Table 11.5]. Among patients trans-
planted, there has been a 21% decrease in transplants in
the 50–64 year age group, with a concomitant rise in trans-
plants performed in the very young and older patients. The
distribution of organs between male and female recipients
has been stable, with 26% of grafts going to women. There
has been a 20% reduction in the number of white recipi-
ents, with a concomitant rise in transplants performed in
the other major ethnicity/racial groups. A drop of 29% was
seen in the number of patients transplanted with a diag-
nosis of coronary artery disease while there has been an
increase in the proportion of patients transplanted for pri-
mary cardiomyopathy during the same period [Table 11.4].
These changes, in part, shadow reductions in white pa-
* Denotes time point of policy change promoting broader geographic sharing 
of organs for higher status patients 
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Figure 6: Annual death rates per
1000 patient-years on the heart
waiting list by status, 2001–
2007.
tients and those with coronary artery disease listing for
transplantation. Retransplantation occurred in 4.4% of the
2007 cohort. From a population standpoint, the number
of heart transplants performed (incidence) has fallen from
8.7 to 7.3 recipients per million; there also is wide state-to-
state variability, from 0 to approximately 15 recipients per
million [Table 11.5]. On the other hand, the overall num-
bers (prevalence) of heart transplant recipients within our
society has risen from 14 810 in 1998 to 18 742 in 2006
[Table 11.16].
Between the inception of the new classification system
in 1999 and 2007, the distribution of patients among the
different status groups at the time of heart transplantation
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Source: 2008 OPTN/SRTR Annual Report, Tables 11.4 and 11.5 .
Figure 7: Number of heart trans-
plants and incidence of transplant
per million population, 1998–2007.
has shifted toward the more urgent statuses. In 1999, pa-
tients transplanted as Status 1A, 1B and 2 comprised 34%,
36% and 26% of the entire cohort, respectively. In 2007,
these proportions were 50%, 36% and 14%, respectively
(Figure 8) [Table 11.4]. This change is likely attributable to
the wider geographic sharing of donor hearts for candi-
dates listed as Status 1A or 1B, a result of the change in
the donor heart allocation process approved by the OPTN
Board of Directors in November 2005 and implemented in
July 2006. The policy was expected to lead to a decrease
in Status 2 transplants in favor of candidates listed at a
more urgent status. In the years before and after this pol-
icy change, the percentage of transplanted patients with
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Source: 2008 OPTN/SRTR Annual Report, Table 11.4 .
Figure 8: Status of heart transplant
recipients, 2001–2007.
remained similar (38% in 2005 vs. 37% in 2007). From
2005 to 2007, the increase in the proportion of donor or-
gans with cold ischemia time between 271 and 360 min
was <1%, and the increase in the proportion between 180
and 270 min only 4%. Other cold ischemia time categories
showed even less of an increase or no increase at all [Table
11.4].
Heart Transplant Outcomes
Patient survival, adjusted for age, sex, ethnicity/race and
diagnosis across the entire cohort of patients have now
reached 93%, 88%, 81%, 74% and 55% at 3 months, 1,
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Figure 9: Adjusted short- and long-
term survival of heart recipients, by
year of transplant, 1995–2006.
3, 5 and 10 years, respectively (Figure 9) [Table 11.13].
In addition, there have been substantial improvements in
survival as experience has accrued. For example, 3-month
survival was noted to improve from 86% to 93% in patients
transplanted in 1987 and 2006, respectively. Likewise, 10-
year survival has improved from 46% to 55% for patients
transplanted in 1987 and 1997, respectively. More recent
patients have not yet accrued enough time following trans-
plantation to determine actual survival.
Recent-era adjusted patient survival after heart transplan-
tation at 3 months, 1 and 5 years posttransplant is simi-
lar across the range of adult patient ages, but there is a
marked decrease in survival at 10 years for patients 65
years and older (54%, 57%, 55% and 44%, for age groups
18–34, 35–49, 50–64 and 65 years and older, respectively)
[Table 11.12].
At all time points, survival is slightly lower for women
than for men. As an example, 5-year survival for men



























Figure 10: Annual death rate per
1000 patient-years at risk for re-
cipients during first year after
heart transplantation, 1998–2006.
transplanted in 2001 or after is 75%, whereas survival for
women in the same era is 72%. In addition, medium to
long-term survival for African Americans is lower than in
other ethnic/racial groups. For example, although 3-month
survival is 92.5% and 92.6% for white and African Amer-
ican recipients, respectively, there is a divergence in sur-
vival that is seen 1-year posttransplant; 10-year survival
is 57.2% and 43.9%, respectively, for whites and African
Americans [Table 11.12].
Adjusted survival rates for the pediatric population show
somewhat different trends from adults. The lowest 3-
month survival rate in all groups (including adults) is for
recipients less than 1 year of age (85%), likely related to
the technical challenges posed in surgical procedures for
these very tiny patients [Table 11.12]. However, the high-
est 10-year survival is in that same group of recipients
(66%), possibly related to the immaturity of the immune
system in infancy. This would lead to a higher degree of tol-
erance and to presumably less transplant coronary artery
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Source: 2008 OPTN/SRTR Annual Report, Table 11.7 .
Figure 11: Annual death rate per
1000 patient-years at risk during
first year after heart transplanta-
tion by status, 2002–2006.
disease and other forms of graft failure. Survival figures for
children and adolescents lie between those of infancy and
adulthood at 10 years following heart transplantation.
Death rates in the first year after heart transplantation have
steadily decreased, from 168 deaths per 1000 patient-
years at risk in 1998 to 136 deaths per 1000 patient-years
at risk in 2006 (Figure 10) [Table 11.7]. All four adult pa-
tient age groups, 18–34, 35–49, 50–64 and 65 years and
older have demonstrated a decrease in death rates in the
first year over the same period. The largest decrease in the
death rate has, in fact, occurred in the 65 years and older
age group, from 242 to 145 deaths per 1000 patient-years
at risk. There has been wide variability in death rates in the
pediatric populations, likely because the small numbers
preclude meaningful analysis; however, it is apparent that
the highest actual death rates occur in recipients in infancy.
There also has been a decrease in death rates in the first
year after heart transplantation for all status groups since
1999 (the year the current status system for allocation was
implemented; Figure 11) [Table 11.7], as well as across
both sexes and for whites and Hispanic/Latinos. This
trend, however, is not apparent in the other ethnicity/race
groups, including African Americans or Asians (Figure 12)
[Table 11.7].
Although there has been a decrease in the death rate in
the first year after heart transplantation for each individ-
ual adult donor age group since 1998, there remains a
marked increase in the death rate for each progressively
older donor age group (109, 170 and 237 deaths per 1000
patient-years at risk in the 18–34, 35–49 and 50–64-year old
donor groups, respectively) [Table 11.7]. There are too few
donors above the age of 65 years for a meaningful analysis.
The death rates in the first year after transplantation have
decreased for each cold ischemia time group. However,
each progressively longer cold ischemia time grouping has
a corresponding increased death rate (93, 105, 149 and 181
deaths per 1000 patient-years at risk in the 0–90, 91–180,
181–270 and 271–360 min of ischemia time groupings,
respectively).
Patient Care Issues
Ventricular assist devices as a bridge to transplant
Despite aggressive organ donor initiatives, only a tiny frac-
tion of patients with end-stage heart failure are treated by
heart transplantation. In addition, about one patient dies on
the waiting list for every five who receive a heart transplant
(374 deaths on the waiting list vs. 2207 patients trans-
planted in 2007) [Tables 11.3 and 11.4]. Currently, over
64% of heart transplant recipients require life support as a
bridge to transplant [Table 11.4]. This includes intravenous
medications in the intensive care unit, mechanical ventila-
tion, use of intra-aortic balloon pumps, ECLS, total artificial
hearts and VADs. Because of the shortage of available or-
gans for heart transplantation, mechanical circulatory sup-
port has been developed, primarily in the form of LVADs.
Better survival rates have consistently been observed with
devices designed to assist, instead of replace, the left (and
occasionally right) ventricle(s). These VADs are now rou-
tinely used as bridges to transplant, and increasingly as
either ‘destination therapy’ or as ‘bridges to decision’ for
those patients who may need extra time and circulatory
support while determination of transplant suitability is es-
tablished, or occasionally for patients with extreme allo-
sensitization.
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Source: 2008 OPTN/SRTR Annual Report, Table 11.7.
Figure 12: Annual death rates per
1000 patient-years during first year
following heart transplantation by
race/ethnicity, 2002–2006.
Because of the shortcomings of the first generation
devices (volume displacement, pulsatile pumps), new
designs are in development, with the goal of improved
durability (longer possible support times) with fewer com-
plications. Axial flow devices have fewer moving parts and
are smaller, thus better suited for smaller patients, partic-
ularly women and children. These new VADs have thin-
ner, less obtrusive drivelines, with reduced likelihood of
infection. A clinical trial of the HeartMate II LVAD recently
demonstrated improved quality of life and functional sta-
tus in a group of patients supported using the device as a
bridge to transplant (2). This technology has recently gained
Food and Drug Administration (FDA) approval for the indi-
cation of bridge to transplantation.
Increased use of VADs has led to a few notable trends
in heart recipient characteristics, including a 45% reduc-
tion in the number of patients hospitalized in an intensive
care unit before heart transplantation [Table 11.4]. There
has also been a 15% reduction in the number of patients
on a non-VAD form of life support (ECMO, intra-aortic bal-
loon pump, prostaglandins, intravenous inotropes, inhaled
nitric oxide and mechanical ventilation) at the time of heart
transplantation over the past decade. To place this in per-
spective, between July 2006 and July 2008, the proportion
of patients with a VAD at the time of listing was 13.4%.
The proportion, of patients with a VAD ever while listed
for transplant during that same time period was 19.8%
(3), highlighting the fact that VAD technology has a major
impact on patient management as it pertains to cardiac
transplantation.
Ventricular assist technology is in rapid evolution and will
provide a realistic alternative to transplantation in the near
future. However, it has been difficult to integrate VAD use
as a bridge to transplant in allocation policy because of
the paucity of detailed information prospectively collected
for the OPTN database; rapidly changing technology and
outcomes compound this difficulty. The OPTN is aware
of this data gap and is taking steps to collect these data
on VAD placement and timing of placement, particularly
when a status justification form is completed after listing.
Cautious interpretation of these data will be needed.
The recent development of a national registry, the Intera-
gency Registry for Mechanically Assisted Circulatory Sup-
port (INTERMACS), a joint effort of the National Heart,
Lung, and Blood Institute, FDA, and Centers for Medicare
and Medicaid Services aims to help solve this problem.
Only data from patients with FDA approved VADs who
have the potential for discharge are being obtained within
this registry (not intra-aortic balloon pump, ECLS or tem-
porary VADs). Data from INTERMACS should be available
in the next 3–5 years. This is likely to contribute to mean-
ingful change in heart allocation policy for those patients
who require mechanical circulatory support as a bridge to
transplant.
Immunosuppression therapy for heart
transplant recipients
The immunosuppression regimen for heart transplant re-
cipients has continued to evolve over the past decade. In-
duction therapy in the form of equine antithymocyte glob-
ulin (Atgam R©) or muromonab-CD3 (OKT3 R©) was used for
27% of patients in 1998. While use of induction therapy
has gradually increased, reaching 54% in 2007, both these
drugs have been largely replaced by the use of rabbit an-
tilymphocyte globulin (Thymoglobulin R©) in 19% of heart
recipients or monoclonal antibody therapy directed against
the IL-2 receptor, namely, daclizumab (Zenapax R©) or basilix-
imab (Simulect R©), in 27% of heart recipients [Table 11.6a].
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Over the past decade, the overwhelming majority (ap-
proximately 77%) of transplant recipients were discharged
on triple drug therapy consisting of a calcineurin an-
tagonist, mycophenolate mofetil/mycophenolic acid or
other antimetabolite and steroid therapy. The two most
common regimens in 1998 (72% of transplant recipi-
ents) were cyclosporine with either: (a) mycophenolate
mofetil/myocophenolic acid or (b) another antimetabo-
lite and steroids. In 2007, the most common dis-
charge regimen, by far, was tacrolimus, mycophenolate
mofetil/mycophenolic acid and steroids (52% of transplant
recipients), and, to a lesser extent (24% of transplant recip-
ients), cyclosporine, mycophenolate mofetil/mycophenolic
acid and steroids. The use of the mTOR inhibitors sirolimus
(Rapamune R©) or everolimus (Certican R©) at discharge, in var-
ious combinations with other agents, is only 3.4%, likely
out of concern for impaired wound healing in the immedi-
ate postoperative period [Table 11.6d-e].
At 1 year following transplantation, triple drug therapy with
a calcineurin antagonist (principally tacrolimus), mycophe-
nolate mofetil/mycophenolic acid and steroid therapy re-
mains the predominant treatment regimen (approximately
54% of heart recipients). However, since 1997 there has
been a small (approximately 33% of patients) but important
trend toward steroid-free drug regimens by 1 year following
transplantation. The use of either sirolimus or everolimus
in various combinations with other agents between dis-
charge and 1-year posttransplant is approximately 11%,
reflecting the fact that mTOR inhibitors may have utility
in preventing and/or retarding transplant coronary artery
disease [Table 11.f–g].
A notable trend is the declining number of recipients who
needed treatment for rejection episodes during the first
year following transplantation (22% in 2006 compared with
38% in 1997). The overwhelming majority of patients were
treated with steroids (90% of rejection episodes), while ap-
proximately 19% were treated with any form of antibody
therapy, most frequently with rabbit antilymphocyte glob-
ulin [Table 11.6i]. The decline in rejection episodes proba-
bly reflects the improved efficacy of the newer immuno-
suppression medications, but also may result from incre-
mental improvements in the overall care of donors and
recipients.
Heart Allocation Policy Changes
On July 12, 2006, the OPTN Thoracic Organ Transplanta-
tion Committee implemented an allocation policy change
prioritizing Zone A 1A and 1B patients ahead of local (within
the donor service area) Status 2 patients (4). It was pre-
dicted that the policy change would result in fewer deaths
on the waiting list and overall. While not enough data have
accrued to make evaluations with regard to posttransplant
outcomes, initial data do exist to examine the overall rate
of transplantation and experience on the heart waiting list.
In 2005, the last complete year prior to the 2006 policy
change allowing for broader sharing of hearts for the most
urgent patients, there were 469 deaths on the heart wait-
ing list. The number dropped to 374 in 2007, the first com-
plete calendar year for which all transplants occurred under
the new sharing rules [Table 11.3]. The decline in deaths
was noticed in every active status category (148–107 for
Status 1A, 94–73 for Status 1B and 81–51 for Status 2, re-
spectively). There has also been a shift in the proportion of
patients transplanted from the more urgent status groups.
In 2005, 40% and 35% of recipients were transplanted
from status groups 1A and 1B, respectively. In 2007, the
proportion of recipients transplanted from status groups
1A and 1B increased to 50% and 36%, respectively. The
corresponding change in transplants performed was 2125
in 2005 compared with 2207 in 2007 [Table 11.4].
There has been some concern that implementation of
broader sharing could affect posttransplant survival. Specif-
ically, with a shift toward longer ischemia time and a greater
proportion of patients transplanted from the more urgent
status groups (and thus potentially a sicker patient popu-
lation), posttransplant survival, in theory, could be dimin-
ished. In fact, survival has not changed appreciably, at
least out to one year following transplantation. In addi-
tion, although there is a nonstatistically significant trend
toward improved survival for Status 1A patients, 1-year
posttransplant survival across the status groups remains
unchanged (3).
In July 2006, the OPTN Pediatric Transplantation Commit-
tee was charged with developing a plan to reduce the num-
ber of deaths on the pediatric organ transplant waiting lists.
In prior years, although the distribution of adolescent donor
hearts (11–17 year old) were preferentially offered to pedi-
atric candidates prior to adult candidates within each of the
status categories and zones, this was not true for ‘young’
donors (age 0–10 years). Thus, the Pediatric and Thoracic
Organ Transplantation committees suggested that these
young donors follow an algorithm similar to that used with
adolescent donor organs so as to share all pediatric organs
more broadly to the sickest candidates.
In reviewing past performance, it was recognized that a
sizeable proportion of ‘young’ donor heart offers made to
adult recipients are refused owing to size mismatch, while
a reasonable number of such ‘young’ donor organs are
transplanted into adolescents. Moreover, the waiting list
mortality for recipients in this younger age range (especially
ages 1–5 years) remains substantial.
Accordingly, by the proposed plan, pediatric (age 0–17
years) donor offers would be allocated first to combined
local and Zone A (within 500 nautical miles of the donor
center) pediatric Status 1A candidates, then to local adult
Status 1A candidates, then to combined local and Zone
A pediatric Status 1B candidates, before then being of-
fered to adults and pediatric candidates according to the
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prior algorithm. Historically, only 0.5% of adults received
hearts from pediatric donors less than 12 years old. Thus,
the likelihood of this affecting adult waiting list survival is
small; the possibility of it improving outcomes for those
pediatric patients locally and in Zone A, however, is real.
These proposed allocation changes have been approved by
the OPTN Board of Directors as of June 2008 and will be
evaluated in future reports as data are accrued (5).
Summary
The past decade has seen many changes in the field of
heart transplantation. Despite the fact that heart failure
is increasingly prevalent in our society, the number of
patients who are listed for heart transplantation has de-
clined. In addition, the number of actual heart transplants
performed in the United States has fluctuated, with no
real evidence that the number of donors has increased.
Fortunately, the death rate of those listed for organ trans-
plantation has declined significantly. For those who do un-
dergo transplantation, survival has improved significantly,
as posttransplant management strategies have become
more sophisticated, balancing side effects with the bene-
ficial effects of chronic immunosuppression. The addition
of ventricular assist technology, a rapidly changing field,
has added to our ability to manage the most critically ill of
all listed patients, and may, in the very near future, offer
a viable alternative to transplantation for a proportion of
patients with end-stage heart failure.
Certainly, some of the improvements in outcomes seen
in waiting list and posttransplant heart failure patients are
related to policy change. The process of allocating donor
hearts to patients on the waiting list has undergone sub-
stantial change over time, thus allowing broader sharing
of organs to those most in need. However, there are still
several groups of patients, such as those with restrictive
cardiomyopathy, hypertrophic cardiomyopathy, congenital
diseases and those with life-threatening arrhythmic sub-
strate and/or extreme coronary artery disease, who may
not be optimally served by our current methods of alloca-
tion. In addition, unlike the lung allocation system (6), which
allocates organs based on medical urgency and expected
posttransplant survival, allocation policy for the available
pool of donor hearts is largely determined by medical ur-
gency alone. In fact, the majority of organs are allocated to
patients within status groups 1A and 1B, and discrimina-
tion between individual patients within these status groups
is crude at best. Investigation as to the possibility of fur-
ther allocation policy modification is ongoing in the hope
of improving outcomes and promoting more equitable dis-
tribution of hearts.
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